Idsk -- The Food and Drug Administration on Oct. 13 issued a warning about the “possible” risk of the rare atypical femur fractures associated with bisphosphonate treatment in osteoporosis patients, after reviewing the final report on this association released last month by the American Society for Bone and Mineral Research.
